Document Detail

Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.
MedLine Citation:
PMID:  9815887     Owner:  NLM     Status:  MEDLINE    
Transforming growth factor alpha-Pseudomonas exotoxin-40 (TP40) is a hybrid fusion protein that selectively binds to cancer cells that express the epidermal growth factor receptor. TP40 is then internalized and kills these cells by virtue of its Pseudomonas exotoxin-derived domains. We studied the safety and short-term antitumor activity of intravesical TP40 in 43 patients with refractory superficial bladder cancer. These patients had resected Ta/T1 disease (n = 19), visible Ta or T1 lesions (n = 11), or carcinoma in situ (n = 13). Patients were treated with increasing dose levels of TP40 at 0.15, 0.3, 0.6, 1.2, 2.4, 4.8, or 9.6 mg/week for 6 weeks and evaluated by comparing pretreatment and posttreatment cystoscopic examinations, cytology, and histopathology. All TP40 doses were well tolerated. No evidence of antitumor activity was seen in any of the patients with Ta or T1 lesions. However, 8 of 9 patients with evaluable carcinoma in situ were judged by histopathology of multiple biopsy specimens to exhibit clinical improvement following TP40 therapy. In most of these responsive patients, cystoscopic examination supported the histopathological findings, although cytology of urine and bladder washings persistently demonstrated malignant cells. Therefore, TP40 appears to be a well-tolerated biological agent that may prove to have utility in treating carcinoma in situ of the bladder.
M R Goldberg; D C Heimbrook; P Russo; M F Sarosdy; R E Greenberg; B J Giantonio; W M Linehan; M Walther; H A Fisher; E Messing
Related Documents :
16001997 - Breast carcinoma metastatic to the bladder and renal pelvis requiring fulguration.
15254717 - Mitochondrial dna mutations in chemical carcinogen-induced rat bladder and human bladde...
17627177 - Squamous cell carcinoma of the bladder following ptfe implantation.
11696817 - Analysis of the gene expression of sparc and its prognostic value for bladder cancer.
6367857 - Adjuvant therapy of breast cancer: the southwest oncology group experience.
19864507 - Variability in interpretive performance at screening mammography and radiologists' char...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  1     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  1995 Jan 
Date Detail:
Created Date:  1999-02-09     Completed Date:  1999-02-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  57-61     Citation Subset:  IM    
Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Carcinoma in Situ / drug therapy*,  pathology
Dose-Response Relationship, Drug
Exotoxins / adverse effects*
Middle Aged
Neoplasm Staging
Transforming Growth Factor alpha / adverse effects*
Urinary Bladder Neoplasms / drug therapy*,  pathology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Exotoxins; 0/Transforming Growth Factor alpha; 0/transforming growth factor alpha-Pseudomonas exotoxin A (40)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to ...
Next Document:  Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelo...